Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KIF18A | Q8NI77 | 3/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31346241 | 1.00 | ADRB1 (0.39) | ADRB1LRRK2SCN10APDK1PDK2 | |
| SCHEMBL30476654 | 0.80 | HRH4 (0.51) | ADRB1LRRK2ACACBHRH4 | |
| SCHEMBL21812444 | 0.80 | HRH4 (0.47) | ADRB1LRRK2ACACBHRH4 | |
| SCHEMBL30665756 | 0.80 | HRH4 (0.47) | ADRB1LRRK2ACACBHRH4 | |
| SCHEMBL789776 | 0.80 | HRH4 (0.51) | ADRB1LRRK2ACACBHRH4 | |
| SCHEMBL22119280 | 0.80 | OPRD1 (0.54) | ADRB1OPRD1KIF18A | |
| SCHEMBL30619312 | 0.80 | OPRD1 (0.54) | ADRB1OPRD1KIF18A | |
| SCHEMBL29609326 | 0.80 | GRIN2D (0.50) | ADRB1LRRK2PDK1PDK2OPRD1 | |
| SCHEMBL24405849 | 0.79 | HRH4 (0.54) | ADRB1LRRK2CNR2HRH4 | |
| SCHEMBL30701056 | 0.78 | LRRK2 (0.44) | LRRK2OPRD1KIF18AFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856736-B1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-12522593-B2 | Azacycloalkyl carbonyl cyclic amine compound | ALIVEXIS, INC. (JP) | 2026-01-13 | — | — | US | disclosed |
| US-20250163041-A1 | AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND | ALIVEXIS, INC. (JP) | 2025-05-22 | — | — | US | disclosed |
| EP-4538264-A1 | AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND | Alivexis, Inc. (JP) | 2025-04-16 | — | — | EP | disclosed |
| US-12202816-B2 | Compounds as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2025-01-21 | — | — | US | disclosed |
| WO-2023243601-A1 | AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND | モジュラス株式会社 | 2023-12-21 | — | — | WO | disclosed |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2022-02-03 | — | — | US | disclosed |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2022-02-03 | — | — | US | disclosed |
| EP-3856736-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2021-08-04 | — | — | EP | disclosed |
| CN-112930346-A | Novel compounds as NADPH oxidase inhibitors | 金其尤泰克斯瑞士股份有限公司 | 2021-06-08 | — | — | CN | disclosed |
| WO-2020065048-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2020-04-02 | — | — | WO | disclosed |
| EP-3628669-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2020-04-01 | — | — | EP | disclosed |
| EP-3628669-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2020-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163041-A1 | AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND | NCF1, ELANE, MPO | ADRB1 1622/4885LRRK2 1322/4885SCN10A 155/4885 |
| US-12202816-B2 | Compounds as NADPH oxidase inhibitors | CYBB, NOX1, NOX4 | ADRB1 1736/4885LRRK2 2586/4885SCN10A 1351/4885 |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CYBB, NOX1, NOX4 | ADRB1 1712/4885LRRK2 2528/4885SCN10A 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.